Trials / Completed
CompletedNCT06815965
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- EIP Pharma Inc · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | neflamapimod | Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules. |
Timeline
- Start date
- 2024-10-16
- Primary completion
- 2026-03-11
- Completion
- 2026-03-25
- First posted
- 2025-02-10
- Last updated
- 2026-04-08
Locations
2 sites across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06815965. Inclusion in this directory is not an endorsement.